GlobeNewswire

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
14/05/2026
– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of wholly-owned pipeline, [...]
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
14/05/2026
VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, [...]
CapsoVision Reports First Quarter 2026 Financial Results
14/05/2026
SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported [...]
SRx Health Solutions Announces Fiscal Second Quarter 2026 Results for Quarter Ended March 31, 2026
14/05/2026
Q2 FY26 Marks Operational Inflection Point with Sequential 23% Revenue Growth and 44% Adjusted EBITDA Loss 1 Improvement Strengthened Liquidity and Working Capital Position with Cash of $20.5 million as of Quarter End [...]
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights
14/05/2026
-- Zola ® volumes increase 18% year-over-year -- -- SG&A at lowest level in Arcadia’s history -- DALLAS, May 14, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc . ® (Nasdaq: RKDA), a producer and marketer of [...]
BioStem Technologies Reports First Quarter 2026 Financial Results
14/05/2026
POMPANO BEACH, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue [...]
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
14/05/2026
Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ Therapy Platform Enabled [...]
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
14/05/2026
Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million Q1 2026 fully [...]
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
14/05/2026
Strengthened balance sheet and advancing clinical pipeline with multiple catalysts expected through 2027 SOLANA BEACH, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “ [...]
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
14/05/2026
In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of FcεRI-driven pathology versus remibrutinib In healthy volunteers, both single- and [...]
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
Enrollment completed in ML-007C-MA’s Phase 2 ZEPHYR trial in schizophrenia, with topline results expected by mid-August 2026 Last patient visit completed for ML-004’s Phase 2 IRIS trial in autism spectrum disorder, with [...]
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
14/05/2026
NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scale Chief [...]
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026
- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway - - Strengthened balance sheet through financing transactions and Daewoong note exchange, [...]
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product [...]
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
14/05/2026
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced [...]
Elutia to Present at the 16th Annual LD Micro Invitational on May 18th
14/05/2026
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer [...]
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
14/05/2026
Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503 in chronic [...]
Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
14/05/2026
SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum